Meet the chief US ACTA negotiator: Kira Alvarez, the Deputy Assistant USTR for IP Enforcement

Kira Alvarez is the Deputy Assistant USTR for Intellectual Property Enforcement, and the chief US negotiator for ACTA. According to her Linkedin bio, as late as October 2008, right before the election, she was the Time Warner Vice President for Global Public Policy, and before that, she was a lobbyist for Ely Lilly, the pharmaceutical company. Continue Reading

Uncategorized

2009: PAHO dispute over standards for transparency of economic data for pharmaceutical industry

Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:

Continue Reading

Views of Civil Society on USTR Review of Trade-Related Transparency Policies

As mentioned in an earlier KEI blog, on Thursday, March 19, a group of public interest groups met with the Obama administration’s trade officials. As a result of this meeting, USTR has promised to review its policies on transparency and invited groups to submit concrete proposals for evaluation. Further, these proposals are to be discussed as part of the review process in a follow up meeting next month.

Proposed areas of discussion include:

Continue Reading

Impact of the HIF on generic industry in developing countries

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”

Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Continue Reading

Uncategorized